Legend Biotech enters the post-earnings period with short sellers accelerating and the Street sharply divided — a collision that makes this week's setup unusually charged.
Short interest has become the dominant story. It now stands at 11% of free float — up 22% in a single week and nearly 70% higher than a month ago. The speed of the buildup is striking: from roughly 12.1 million shares short on July 1 to more than 20.4 million today, a near-doubling in six weeks. The ORTEX short score has climbed to 77.8, its highest reading in the available history and in the bottom 6th percentile of the universe on the short-score rank — a signal that the data increasingly favours bearish positioning. Borrow availability has tightened sharply alongside the positioning shift, dropping from above 130% through most of July to just 24.3% — the lowest of the past year. That means roughly one share remains available for every four already lent out. Borrowing costs have risen 40% on the week to 0.86%, though in absolute terms they remain modest. The borrow market is tightening fast; it is not yet expensive.
Options positioning confirms the bull-heavy skew in the market, which creates an interesting contrast with the short interest picture. The put/call ratio has collapsed to 0.40 — nearly two standard deviations below its 20-day mean of 0.44 and the lowest level in a year, touching close to the 52-week low of 0.37. That reflects heavy call positioning relative to puts, suggesting a portion of the market is positioned for recovery even as short sellers build. The divergence is the tension worth watching: shorts are pressing while options traders remain leaning long.
Analyst reaction to the earnings print was swift and largely negative. Oppenheimer delivered the most forceful cut, downgrading from Outperform to Perform and slashing its target from $75 to $40 — a move that signals serious concern about the near-term commercial trajectory for Carvykti. TD Cowen trimmed its Hold target from $29 to $24. Barclays and RBC both maintained positive ratings but cut targets, to $78 and $58 respectively. The lone upward move came from Morgan Stanley, which nudged its Overweight target to $49 from $48. The consensus sits at Hold, with five buys and five holds, and a mean target of $49.31 — more than double the current price of $21.83. That gap is wide enough to warrant a flag: it likely reflects pre-earnings targets that have not yet been fully revised, and the direction of travel today is clearly downward revisions. The bull case centres on Carvykti's long-run market potential in multiple myeloma and earlier-line expansion; the bear case points to data generalisation risks from a China-heavy dataset, manufacturing capacity constraints, and the competitive CAR-T landscape.
FMR (Fidelity) remains the largest external institutional holder at 14.9% of shares, and notably added 3.3 million shares in the most recent reported period to July 31 — the most recent institutional data available. Deerfield, Montanova, and Point72 all added positions in Q1 2026, though those filings are now several months old. Insider activity has been limited to small CEO and director sales in June, each below $90,000 in value and carrying low trade-significance scores — more consistent with routine plan sales than conviction selling.
The one prior earnings reaction in the history available — May 2026 — saw the stock fall 6.1% the day after results, then recover 16% over the following five days. The stock has already rallied 14% this week to $21.83, with a further 5.7% gain on August 11 alone, suggesting some of the post-print repricing has already run. Another earnings event is flagged for August 21 — the next print and any accompanying Carvykti commercial update will be the clearest test of whether this week's short buildup proves well-placed or sets the stage for a squeeze.
See the live data behind this article on ORTEX.
Open LEGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
